Report Detail
Global Xeljanz (tofacitnib) Drug Market Insights, Forecast to 2025
- RnM2703988 |
- 22 May, 2019 |
- Global |
- 113 Pages |
- QYResearch |
- Pharma & Healthcare
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis
The global Xeljanz (tofacitnib) Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Xeljanz (tofacitnib) Drug market based on company, product type, end user and key regions.
This report studies the global market size of Xeljanz (tofacitnib) Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Xeljanz (tofacitnib) Drug in these regions.
This research report categorizes the global Xeljanz (tofacitnib) Drug market by top players/brands, region, type and end user. This report also studies the global Xeljanz (tofacitnib) Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Market size by Product
Tablets
Extended-release Tablets
Market size by End User
Rheumatoid Arthritis
Psoriatic Arthritis
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Xeljanz (tofacitnib) Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Xeljanz (tofacitnib) Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Xeljanz (tofacitnib) Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Xeljanz (tofacitnib) Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Xeljanz (tofacitnib) Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Xeljanz (tofacitnib) Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Xeljanz (tofacitnib) Drug Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Xeljanz (tofacitnib) Drug Market Size Growth Rate by Product
- 1.4.2 Tablets
- 1.4.3 Extended-release Tablets
- 1.5 Market by End User
- 1.5.1 Global Xeljanz (tofacitnib) Drug Market Size Growth Rate by End User
- 1.5.2 Rheumatoid Arthritis
- 1.5.3 Psoriatic Arthritis
- 1.5.4 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Xeljanz (tofacitnib) Drug Market Size
- 2.1.1 Global Xeljanz (tofacitnib) Drug Revenue 2014-2025
- 2.1.2 Global Xeljanz (tofacitnib) Drug Sales 2014-2025
- 2.2 Xeljanz (tofacitnib) Drug Growth Rate by Regions
- 2.2.1 Global Xeljanz (tofacitnib) Drug Sales by Regions
- 2.2.2 Global Xeljanz (tofacitnib) Drug Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Xeljanz (tofacitnib) Drug Sales by Manufacturers
- 3.1.1 Xeljanz (tofacitnib) Drug Sales by Manufacturers
- 3.1.2 Xeljanz (tofacitnib) Drug Sales Market Share by Manufacturers
- 3.1.3 Global Xeljanz (tofacitnib) Drug Market Concentration Ratio (CR5 and HHI)
- 3.2 Xeljanz (tofacitnib) Drug Revenue by Manufacturers
- 3.2.1 Xeljanz (tofacitnib) Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Xeljanz (tofacitnib) Drug Revenue Share by Manufacturers (2014-2019)
- 3.3 Xeljanz (tofacitnib) Drug Price by Manufacturers
- 3.4 Xeljanz (tofacitnib) Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Xeljanz (tofacitnib) Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Xeljanz (tofacitnib) Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Xeljanz (tofacitnib) Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Xeljanz (tofacitnib) Drug Sales by Product
- 4.2 Global Xeljanz (tofacitnib) Drug Revenue by Product
- 4.3 Xeljanz (tofacitnib) Drug Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Xeljanz (tofacitnib) Drug Breakdown Data by End User
6 North America
- 6.1 North America Xeljanz (tofacitnib) Drug by Countries
- 6.1.1 North America Xeljanz (tofacitnib) Drug Sales by Countries
- 6.1.2 North America Xeljanz (tofacitnib) Drug Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Xeljanz (tofacitnib) Drug by Product
- 6.3 North America Xeljanz (tofacitnib) Drug by End User
7 Europe
- 7.1 Europe Xeljanz (tofacitnib) Drug by Countries
- 7.1.1 Europe Xeljanz (tofacitnib) Drug Sales by Countries
- 7.1.2 Europe Xeljanz (tofacitnib) Drug Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Xeljanz (tofacitnib) Drug by Product
- 7.3 Europe Xeljanz (tofacitnib) Drug by End User
8 Asia Pacific
- 8.1 Asia Pacific Xeljanz (tofacitnib) Drug by Countries
- 8.1.1 Asia Pacific Xeljanz (tofacitnib) Drug Sales by Countries
- 8.1.2 Asia Pacific Xeljanz (tofacitnib) Drug Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Xeljanz (tofacitnib) Drug by Product
- 8.3 Asia Pacific Xeljanz (tofacitnib) Drug by End User
9 Central & South America
- 9.1 Central & South America Xeljanz (tofacitnib) Drug by Countries
- 9.1.1 Central & South America Xeljanz (tofacitnib) Drug Sales by Countries
- 9.1.2 Central & South America Xeljanz (tofacitnib) Drug Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Xeljanz (tofacitnib) Drug by Product
- 9.3 Central & South America Xeljanz (tofacitnib) Drug by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Xeljanz (tofacitnib) Drug by Countries
- 10.1.1 Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Countries
- 10.1.2 Middle East and Africa Xeljanz (tofacitnib) Drug Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Xeljanz (tofacitnib) Drug by Product
- 10.3 Middle East and Africa Xeljanz (tofacitnib) Drug by End User
11 Company Profiles
- 11.1 Pfizer
- 11.1.1 Pfizer Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Pfizer Xeljanz (tofacitnib) Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Pfizer Xeljanz (tofacitnib) Drug Products Offered
- 11.1.5 Pfizer Recent Development
12 Future Forecast
- 12.1 Xeljanz (tofacitnib) Drug Market Forecast by Regions
- 12.1.1 Global Xeljanz (tofacitnib) Drug Sales Forecast by Regions 2019-2025
- 12.1.2 Global Xeljanz (tofacitnib) Drug Revenue Forecast by Regions 2019-2025
- 12.2 Xeljanz (tofacitnib) Drug Market Forecast by Product
- 12.2.1 Global Xeljanz (tofacitnib) Drug Sales Forecast by Product 2019-2025
- 12.2.2 Global Xeljanz (tofacitnib) Drug Revenue Forecast by Product 2019-2025
- 12.3 Xeljanz (tofacitnib) Drug Market Forecast by End User
- 12.4 North America Xeljanz (tofacitnib) Drug Forecast
- 12.5 Europe Xeljanz (tofacitnib) Drug Forecast
- 12.6 Asia Pacific Xeljanz (tofacitnib) Drug Forecast
- 12.7 Central & South America Xeljanz (tofacitnib) Drug Forecast
- 12.8 Middle East and Africa Xeljanz (tofacitnib) Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Xeljanz (tofacitnib) Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Xeljanz (tofacitnib) Drug . Industry analysis & Market Report on Xeljanz (tofacitnib) Drug is a syndicated market report, published as Global Xeljanz (tofacitnib) Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Xeljanz (tofacitnib) Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
